Bionomics to Participate in Upcoming September Investor Conferences
ADELAIDE, Australia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will participate in the following upcoming investor conferences in September:
- Citi’s 17th Annual BioPharma Conference
- Taking place in-person in Boston on September 8th
- H.C. Wainwright 24th Annual Global Investment Conference
- Company Presentation: September 12th at 12:30pm ET in New York City
- Ladenburg Thalmann Healthcare Conference 2022
- Company Presentation: September 29th at 4:00pm ET in New York City
An audio webcast link for select events, when available, will be posted to Bionomics’ website in the Events and Presentations page of the Investors section.
Released on authority of the Executive Chairman.
FOR FURTHER INFORMATION PLEASE CONTACT:
| Investor RelationsMr. Connor BernsteinVice President, Strategy and Corporate Development+1 (650) 524-5143[email protected] | Investor RelationsKevin Gardner[email protected] |
About Bionomics LimitedBionomics (ASX:BNO, NASDAQ: BNOX) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.www.bionomics.com.au
Source: Bionomics Ltd
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tax Lien Wealth Builders Named No. 3212 on the 2026 Inc. 5000 List
- The Baja Is Back: A Race Against Blindness Offers One Final Chance to Win $350,000 Adventure Truck Prize
- 5 Best Crypto Presales as Upbit Adds Four Tokens and Fresh Listings Send Prices Jumping
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Citi, Ladenburg Thalmann Financial Services, H.C. WainwrightSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share